Posts Tagged ‘androgen receptor’

URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>

Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.

Read Full Post »

URO TODAY: Researchers in Canada have reviewed the vast range of drugs now being used to treatment prostate cancer. These include:

  • drugs that induce androgen deprivation, that is, LHRH antagonists;
  • more active or less toxic chemotherapy agents;
  • immunologic approaches, including passive and active immunization;
  • drugs that target the androgen receptor and/or androgen synthesis;
  • drugs that target specific pathways, including tyrosine kinase inhibitors, angiogenesis inhibitors, endothelin antagonists and matrix metalloproteinase inhibitors;
  • and antioxidants and cell cycle inhibitors.

READ MORE> (but note, you need to subscribe – that is, pay – to see the article).

Read Full Post »

PSA RISING: An extract of the Chinese herb Wedelia (a member of the sunflower family of plants) shrinks the androgen receptor and prostate cancer in mice, according to a study published in Clinical Cancer Research. READ MORE>

Read Full Post »

NEWSWITHVIEWS.COM: Any man not wanting prostate cancer in the first place or who is treating this problem should spend some time understanding at least the basics of the androgen receptor. READ MORE>

Read Full Post »

JULY 29: URO TODAY: Just how prostate cancer finds a way to defeat hormone therapy is been clarified by a new study. READ MORE>

The androgen receptor – a protein ignition switch for prostate cancer cell growth and division – is a master of adaptability.

When drug therapy deprives the receptor of androgen hormones, thereby halting cell proliferation, the receptor manages to find an alternate growth route.

A new study by Dana-Farber Cancer Institute and Ohio State University scientists demonstrates how.

Read Full Post »